OM
Opaleye Management Portfolio holdings
AUM
$494M
1-Year Return
68.17%
This Quarter Return
-9.45%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$449M
AUM Growth
-$122M
(-21%)
Cap. Flow
-$52.3M
Cap. Flow
% of AUM
-11.66%
Top 10 Holdings %
Top 10 Hldgs %
73.91%
Holding
54
New
15
Increased
8
Reduced
14
Closed
9
Top Buys
| 1 |
SNWV
SANUWAVE Health, Inc. Common Stock
SNWV
|
$34.4M |
| 2 |
Immunome
IMNM
|
$10.2M |
| 3 |
Liquidia Corp
LQDA
|
$8.29M |
| 4 |
Anika Therapeutics
ANIK
|
$5.94M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$4.82M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$68M |
| 2 |
Ocular Therapeutix
OCUL
|
$20.1M |
| 3 |
Trevi Therapeutics
TRVI
|
$9.58M |
| 4 |
Jasper Therapeutics
JSPR
|
$8.55M |
| 5 |
NewAmsterdam Pharma
NAMS
|
$8.35M |
Sector Composition
| 1 | Healthcare | 97.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ESSA Pharma
EPIX
$11M
| $3.49M | 0.78% |
2,209,998
| – | – |
|
27
Zentalis Pharmaceuticals
ZNTL
$128M
| $3.16M | 0.7% |
1,985,000
+217,500
| +12% | +$346K |
|
|
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
| $2.71M | 0.6% |
666,503
-83,497
| -11% | -$340K |
|
29
Zymeworks
ZYME
$1.07B
| $2.08M | 0.46% |
+175,000
| New | +$2.08M |
|
30
Biodesix
BDSX
$65M
| $2.02M | 0.45% |
3,225,000
-240,000
| -7% | -$150K |
|
31
Stoke Therapeutics
STOK
$1.08B
| $2M | 0.44% |
300,000
+275,000
| +1,100% | +$1.83M |
|
|
MBX
32
MBX Biosciences, Inc. Common Stock
MBX
$434M
| $1.85M | 0.41% |
+250,000
| New | +$1.85M |
|
|
OPTN
33
DELISTED
OptiNose
OPTN
| $1.77M | 0.39% |
+193,039
| New | +$1.77M |
|
|
IRD
34
Opus Genetics, Inc. Common Stock
IRD
$76.7M
| $1.55M | 0.34% |
+1,175,000
| New | +$1.55M |
|
35
iBio
IBIO
$15.9M
| $1.51M | 0.34% |
375,000
| – | – |
|
36
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $1.39M | 0.31% |
+62,501
| New | +$1.39M |
|
37
Nurix Therapeutics
NRIX
$697M
| $1.37M | 0.3% |
115,000
-263,500
| -70% | -$3.13M |
|
38
Rezolute
RZLT
$642M
| $1.35M | 0.3% |
465,000
| – | – |
|
39
Sangamo Therapeutics
SGMO
$160M
| $692K | 0.15% |
+1,055,000
| New | +$692K |
|
40
PepGen
PEPG
$42M
| $590K | 0.13% |
420,000
+310,000
| +282% | +$436K |
|
41
Journey Medical
DERM
$186M
| $409K | 0.09% |
+69,323
| New | +$409K |
|
42
Ventyx Biosciences
VTYX
$185M
| $219K | 0.05% |
190,000
-90,000
| -32% | -$104K |
|
|
ADGM
43
Adagio Medical Holdings, Inc Common Stock
ADGM
$25.4M
| $92.1K | 0.02% |
110,571
| – | – |
|
44
AbCellera Biologics
ABCL
$1.24B
| – | – |
-965,000
| Closed | -$2.83M |
|
45
Immatics
IMTX
$695M
| – | – |
-165,000
| Closed | -$1.17M |
|
|
46
Jasper Therapeutics
JSPR
$43.7M
| – | – |
-400,000
| Closed | -$8.55M |
|
47
Lexeo Therapeutics
LXEO
$268M
| – | – |
-130,000
| Closed | -$855K |
|
48
Regenxbio
RGNX
$476M
| – | – |
-80,000
| Closed | -$618K |
|
49
UroGen Pharma
URGN
$870M
| – | – |
-220,000
| Closed | -$2.34M |
|
|
50
NewAmsterdam Pharma
NAMS
$2.89B
| – | – |
-325,000
| Closed | -$8.35M |
|